CTI BioPharma Corp. (CTIC) financial statements (2021 and earlier)

Company profile

Business Address 3101 WESTERN AVENUE
SEATTLE, WA 98121
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:533467274412871
Cash and cash equivalents403136274412871
Short-term investments12331    
Other undisclosed cash, cash equivalents, and short-term investments00(0)    
Restricted cash and investments   16   
Receivables   0002
Inventory, net of allowances, customer advances and progress billings   1234
Inventory   1234
Other undisclosed current assets221531043
Total current assets:543682475613581
Noncurrent Assets
Property, plant and equipment1122345
Other noncurrent assets3966567
Total noncurrent assets:411788912
TOTAL ASSETS:584690556414492
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities9121716323332
Accounts payable2 437116
Accrued liabilities7121314252220
Employee-related liabilities      6
Taxes payable      0
Debt45508379
Deferred revenue and credits1011
Other liabilities4211120
Other undisclosed current liabilities      (6)
Total current liabilities:17182319417236
Noncurrent Liabilities
Long-term debt and lease obligation 491411198
Long-term debt, excluding current maturities 491411198
Liabilities, other than long-term debt15564512
Deferred revenue and credits0116
Other liabilities1555446
Other undisclosed noncurrent liabilities      (4)
Total noncurrent liabilities:1101420152516
Total liabilities:18283739569752
Temporary equity, carrying amount      1
Stockholders' equity
Stockholders' equity attributable to parent, including:40245922135242
Preferred stock   1   
Common stock000    
Additional paid in capital2,3682,2992,294    
Accumulated other comprehensive income (loss)0(12)(11)(6)(7)(7)(6)
Accumulated deficit(2,328)(2,264)(2,225)(2,195)(2,150)(2,098)(1,976)
Other undisclosed stockholders' equity attributable to parent   2,2222,1702,1572,024
Stockholders' equity attributable to noncontrolling interest (6)(6)(6)(6)(5)(3)
Total stockholders' equity:4018531684738
TOTAL LIABILITIES AND EQUITY:584690556414492

Income statement (P&L) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Revenues 32625571660
Revenue, net25571677
Cost of revenue (1)(5)(0) (2)(1)
Cost of goods and services sold  (1)(0) (2)(1)
Gross profit: 32225571459
Operating expenses(48)(43)(55)(64)(110)(131)(147)
Other operating income, net    5  
Other undisclosed operating income (loss)    (1) 1
Operating loss:(48)(41)(33)(40)(49)(117)(86)
Nonoperating income (expense)(5)14(1)(4)(4)(8)
Investment income, nonoperating(4)11    
Foreign currency transaction gain (loss), before tax(0)(0)(0)1(0)(1)(4)
Other nonoperating income (expense) 14(0)(0)(1)(1)
Interest and debt expense(1)(1)(1)(0)(3)(1)(2)
Loss before gain (loss) on sale of properties:(53)(41)(31)(41)(56)(122)(96)
Other undisclosed net income1110312
Net loss:(52)(40)(29)(41)(53)(121)(94)
Net income attributable to noncontrolling interest 000111
Net loss attributable to parent:(52)(40)(29)(41)(52)(119)(93)
Preferred stock dividends and other adjustments  (0)(4) (3)(3)
Net loss available to common stockholders, diluted:(52)(40)(29)(45)(52)(123)(96)

Comprehensive Income ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Net loss:(52)(40)(29)(41)(53)(121)(94)
Other comprehensive income (loss)0(1)(4)00(0)2
Comprehensive loss:(52)(41)(34)(40)(53)(121)(92)
Comprehensive income, net of tax, attributable to noncontrolling interest 000111
Comprehensive loss, net of tax, attributable to parent:(52)(41)(34)(40)(52)(120)(91)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: